Cited by 1,487Menopause: Health Impacts and TreatmentsEstrogen and related hormone effectsCancer Risks and Factors

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

Open access

Colditz, Graham A., Hankinson, Susan E., Hunter, David J., Willett, Walter C., Manson, JoAnn E., Stampfer, Meir J., Hennekens, Charles, Rosner, Bernard, Speizer, Frank E.·1995·New England Journal of Medicine

DOI 10.1056/nejm199506153322401

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The effect of adding progestins to estrogen therapy on the risk of breast cancer in postmenopausal women is controversial. METHODS: To quantify the relation between the use of hormones and the risk of breast cancer in postmenopausal women, we extended our follow-up of the participants in the Nurses' Health Study to 1992. The women were asked to complete questionnaires every two years to update information on their menopausal status, use of estrogen and progestin preparations, and any diagnosis of breast cancer. During 725,550 person-years of follow-up, we documented 1935 cases of newly diagnosed invasive breast cancer. RESULTS: The risk of breast cancer was significantly increased among women who were currently using estrogen alone (relative risk, 1.32; 95 percent confidence interval, 1.14 to 1.54) or estrogen plus progestin (relative risk, 1.41; 95 percent confidence interval, 1.15 to 1.74), as compared with postmenopausal women who had never used hormones. Women currently taking hormones who had used such therapy for 5 to 9 years had an adjusted relative risk of breast cancer of 1.46 (95 percent confidence interval, 1.22 to 1.74), as did those currently using hormones who had done so for a total of 10 or more years (relative risk, 1.46; 95 percent confidence interval, 1.20 to 1.76). The increased risk of breast cancer associated with five or more years of postmenopausal hormone therapy was greater among older women (relative risk for women 60 to 64 years old, 1.71; 95 percent confidence interval, 1.34 to 2.18). The relative risk of death due to breast cancer was 1.45 (95 percent confidence interval, 1.01 to 2.09) among women who had taken estrogen for five or more years. CONCLUSIONS: The addition of progestins to estrogen therapy does not reduce the risk of breast cancer among postmenopausal women. The substantial increase in the risk of breast cancer among older women who take hormones suggests that the trade-offs between risks and benefits should be carefully assessed.

Integrity signals

Registry

Crossref · 10.1056/nejm199506153322401

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Variations in mortality by weight among 750,000 men and women
Lew, E. A., & Garfinkel, L. (1979) · Journal of Chronic Diseases · doi:10.1016/0021-9681(79)90119-x · Cited by 1,169
Estrogens, Progestogens, Normal Breast Cell Proliferation, and Breast Cancer Risk
Pike, M. C., SPICER, D. V., Dahmoush, L., & Press, M. F. (1993) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036102 · Cited by 1,009
TEST OF THE NATIONAL DEATH INDEX
Stampfer, M. J., Willett, W. C., Speizer, F. E., DYSERT, D. C., LIPNICK, R. J., ROSNER, B. A., & Hennekens, C. H. (1984) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113804 · Cited by 791
The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer
Key, T. J., & Pike, M. C. (1988) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(88)90173-3 · Cited by 658
The Risk of Breast Cancer after Estrogen and Estrogen–Progestin Replacement
Bergkvist, L., Adami, H., Persson, I. R., Hoover, R. N., & Schairer, C. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908033210505 · Cited by 612
The Effect of Postmenopausal Estrogen Therapy on Bone Density in Elderly Women
Felson, D. T., Zhang, Y., Hannan, M. T., Kiel, D. P., Wilson, P. W. F., & Anderson, J. J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310143291601 · Cited by 580
THE EPIDEMIOLOGY OF SERUM SEX HORMONES IN POSTMENOPAUSAL WOMEN
Cauley, J. A., Gutai, J. P., Kuller, L. H., LEDONNE, D., & POWELL, J. G. (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115234 · Cited by 485
Biologic Effects of Transdermal Estradiol
Chetkowski, R. J., Meldrum, D. R., Steingold, K. A., Randle, D., Lu, J. K., Eggena, P., Hershman, J. M., Alkjaersig, N. K., Fletcher, A. P., & Judd, H. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142505 · Cited by 482
Biologic effects of transdermal estradiol
Chetkowski, R. J., Meldrum, D., & Ka, S. (1987) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(87)90325-0 · Cited by 467

Show all 32 references

Research works printed but not linked: 4

Feinleib M, 1968, J Natl Cancer Inst, 41, 315
Committee on the relationship Between Oral Contraceptives and Breast Cancer, Institute of Medicine. Oral contraceptives & breast cancer. Washington, D.C.: National Academy Press, 1991.
Gambrell RD, 1983, Obstet Gynecol, 62, 435
Rose DP, 1977, Obstet Gynecol, 49, 80

Sorted by citations

Items 301–400 of 999

Editorial: Some reflections on cost-effectiveness analysis
Johannesson, M., & Meltzer, D. O. (1998) · Health Economics · doi:10.1002/(sici)1099-1050(199802)7:1 · Cited by 141
Breast cancer incidence subsequent to surgical reduction of the female breast
Baasch, M., Nielsen, S. F., Engholm, G., & Lund, K. P. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.172 · Cited by 67
Problems Involved in Including Women with Simple Hysterectomy in Epidemiologic Studies Measuring the Effects of Hormone Replacement Therapy on Breast Cancer Risk
Pike, M. C., Ross, R. K., & SPICER, D. V. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009515 · Cited by 67
“A number of epidemiologic studies of breast cancer risk have classified women who reported undergoing simple premenopausal hysterectomy without bilateral oophorectomy as being postmenopausal at the age when natural menopause has occurred in a high percentage (S:90 percent) of women (1-3).”
BackgroundMethod
Reduced risk of breast cancer mortality in women using postmenopausal hormone therapy: a Finnish nationwide comparative study
Mikkola, T. S., Savolainen-Peltonen, H. M., Tuomikoski, P., Hoti, F. J., Vattulainen, P., Gissler, M., & Ylikorkala, O. (2016) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000698 · Cited by 66
Norethindrone Acetate and Estradiol-Induced Endometrial Hyperplasia
Kurman, R. J., FÉLIX, J. C., ARCHER, D. F., NANAVATI, N., ARCE, J.-C., & MOYER, D. L. (2000) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(00)00944-3 · Cited by 66
Interactions of isoflavones and other plant derived estrogens with estrogen receptors for prevention and treatment of breast cancer—Considerations concerning related efficacy and safety
Leclercq, G., & Jacquot, Y. (2012) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2012.12.010 · Cited by 65
Postmenopausal hormone therapy and breast cancer risk: The multiethnic cohort
Lee, S. A., Kolonel, L. N., Wilkens, L. R., Wan, P. C., Henderson, B. E., & Pike, M. C. (2005) · International Journal of Cancer · doi:10.1002/ijc.21481 · Cited by 65
Phase III Randomized Placebo-Controlled Trial of Two Doses of Megestrol Acetate as Treatment for Menopausal Symptoms in Women With Breast Cancer: Southwest Oncology Group Study 9626
Goodwin, J. W., Green, S., Moinpour, C. M., Bearden, J. D., Giguere, J. K., Jiang, C. S., Lippman, S. M., Martino, S., & Albain, K. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.6179 · Cited by 65
“24 when progesterones alone were used as HRT.(24) In this study, MA did not impact favorably on menopausal symptoms other than hot flashes.”
MethodInfluential
Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation
Corrao, G., Zambon, A., Conti, V., Nicotra, F., Vecchia, C. L., Fornari, C., Cesana, G., Contiero, P., Tagliabue, G., Nappi, R. E., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm404 · Cited by 65
Exogenous Hormone Use: Oral Contraceptives, Postmenopausal Hormone Therapy, and Health Outcomes in the Nurses’ Health Study
Bhupathiraju, S. N., Grodstein, F., Stampfer, M. J., Willett, W. C., Hu, F. B., & Manson, J. E. (2016) · American Journal of Public Health · doi:10.2105/ajph.2016.303349 · Cited by 65
Utilisation of hormone replacement therapy by women doctors
Isaacs, A., Britton, A. R., & McPherson, K. (1995) · BMJ · doi:10.1136/bmj.311.7017.1399 · Cited by 65
Mammographic Density in Postmenopausal Women Treated with Tibolone, Estriol or Conventional Hormone Replacement Therapy
Valdivia, I., & Ortega, D. (2000) · Clinical Drug Investigation · doi:10.2165/00044011-200020020-00005 · Cited by 65
Oxidative DNA Damage Induced by Equine Estrogen Metabolites: Role of Estrogen Receptor α
Liu, X., Yao, J., Pisha, E., Yang, Y., Hua, Y., van Breemen, R. B., & Bolton, J. L. (2002) · Chemical Research in Toxicology · doi:10.1021/tx0101649 · Cited by 64
Aetiology and Treatment of Sleep Disturbances During Perimenopause and Postmenopause
Polo‐Kantola, P., Saaresranta, T., & Polo, O. J. (2001) · CNS Drugs · doi:10.2165/00023210-200115060-00003 · Cited by 64
Prevention of solely estrogen-induced mammary tumors in female aci rats by tamoxifen: evidence for estrogen receptor mediation
Li, S., Weroha, S., Tawfik, O. W., & Li, J. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1750297 · Cited by 64
Effects of sex steroids on proliferation in normal mammary tissue
Söderqvist, G. (1998) · Annals of Medicine · doi:10.3109/07853899809002598 · Cited by 63
Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy
Bush, T. L. (1996) · European Heart Journal · doi:10.1093/eurheartj/17.suppl_d.9 · Cited by 64
Immunohistochemical studies on Waf1p21, p16, pRb and p53 in human esophageal carcinomas and neighboring epithelia from a high-risk area in northern China
Yang, G., Zhang, Z., Liao, J., Seril, D., Wang, L., Goldstein, S., & Yang, C. S. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970904)72:5 · Cited by 38
Alternative therapies for traditional disease states: menopause.
Morelli, V., & Naquin, C. (2002) · PubMed · Cited by 60
Protective effect of isoflavones from Trifolium pratense on dopaminergic neurons
Chen, H.-Q., Wang, X., Jin, Z., Xu, X., Zhao, J.-W., & Xie, Z. (2008) · Neuroscience Research · doi:10.1016/j.neures.2008.07.001 · Cited by 63
Hormone replacement therapy: controversies, pros and cons
Warren, M. P., & Halpert, S. (2004) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.02.005 · Cited by 62
Impact of menopausal hormone-replacement therapy on clinical and laboratory characteristics of breast cancer
Bonnier, P., Bessenay, F., Sasco, A. J., Beedassy, B., Lejeune, C., Romain, S., Charpin, C., Piana, L., & Martin, P. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(199806)79:3 · Cited by 63
Menopause, hormone replacement therapy and cancer
Vecchia, C. L., Brinton, L. A., & McTiernan, A. (2001) · Maturitas · doi:10.1016/s0378-5122(01)00213-4 · Cited by 63
“A report from the American Nurses Health Study cohort [41] confirmed some excess breast cancer risk among current long-term HRT users: the RRs were 1.”
Background
Effects of dehydroepiandrosterone, Premarin and Acolbifene on histomorphology and sex steroid receptors in the rat vagina
Berger, L., Elalfy, M., Martel, C., & Labrie, F. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2005.02.018 · Cited by 62
The incidence of breast cancer and changes in the use of hormone replacement therapy: A review of the evidence
Verkooijen, H. M., Bouchardy, C., Vinh‐Hung, V., Rapiti, E., & Hartman, M. (2009) · Maturitas · doi:10.1016/j.maturitas.2009.07.015 · Cited by 62
Evidence for gender differences in cognition, emotion and quality of life in Parkinson's disease?
Heller, J., Dogan, I., Schulz, J., & Reetz, K. (2014) · Aging and Disease · doi:10.14366/ad.2014.050063 · Cited by 65
“Nonetheless, it has to be questioned if estrogen should be considered as a therapeutic option in PD, as some findings showed that postmenopausal intake of estrogens involves increased risk of endometrial abnormalities [37], venous thromboembolic events [38, 39], breast cancer [39, 40], coronary heart disease and strok…”
Background
Breast cancer risk in the WHI study: The problem of obesity
Kühl, H. (2005) · Maturitas · doi:10.1016/j.maturitas.2005.02.018 · Cited by 63
Estrogen Therapy and Osteoporosis: Principles & Practice
Notelovitz, M. (1997) · The American Journal of the Medical Sciences · doi:10.1016/s0002-9629(15)40035-7 · Cited by 62
Tibolone protects T98G cells from glucose deprivation
Ávila-Rodriguez, M., García‐Segura, L. M., Cabezas, R., Torrente, D., Capani, F., González, J., & Barreto, G. E. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.07.009 · Cited by 61
The Breast Cancer Epidemic: 10 Facts
Schneider, A., Zainer, C. M., Kubat, C. K., Mullen, N. K., & Windisch, A. (2014) · The Linacre Quarterly · doi:10.1179/2050854914y.0000000027 · Cited by 61
“The 1995 Nurses’ Health Study demonstrated the RR of breast cancer to be 1.5 among post-menopausal women on estrogen plus progestin, but 2.40 among women receiving progestin alone (Colditz et al. 1995).”
BackgroundInfluential
Effects of idoxifene and estradiol on NF‐κB activation in cultured rat hepatocytes undergoing oxidative stress
Omoya, T., Shimizu, I., Zhou, Y., Okamura, Y., Inoue, H., Lu, G., Itonaga, M., Honda, H., Nomura, M., & Ito, S. (2001) · Liver International · doi:10.1034/j.1600-0676.2001.021003183.x · Cited by 60
Estriol: safety and efficacy.
Ka, H. (1998) · PubMed · Cited by 61
Osteoporosis and African American Women
Bohannon, A. (1999) · Journal of Women s Health & Gender-Based Medicine · doi:10.1089/jwh.1.1999.8.609 · Cited by 61
Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro
Michael, H., Härkönen, P. L., Kangas, L., Väänänen, H. K., & Hentunen, T. A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707232 · Cited by 60
“However, a long-term oestrogen therapy also increases a risk of breast and endometrial cancer (Lobo, 1995; Colditz et al., 1995).”
Background
Invited Commentary: Can Selection Bias Explain the Cardiovascular Benefits of Estrogen Replacement Therapy?
Grodstein, F. (1996) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a008679 · Cited by 60
Hormones in Wellness and Disease Prevention: Common Practices, Current State of the Evidence, and Questions for the Future
Schwartz, E., & Holtorf, K. (2008) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2008.07.015 · Cited by 59
Hypocholesterolemic Activity of Raloxifene (LY139481): Pharmacological Characterization as a Selective Estrogen Receptor Modulator
Kauffman, R. F., Bensch, W. R., Roudebush, R. E., Cole, H. W., Bean, J. S., Phillips, D. L., Monroe, A., Cullinan, G. J., Glasebrook, A. L., & Bryant, H. U. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36384-0 · Cited by 59
Pulmonary delivery of drugs for bone disorders
Patton, J. S. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00064-8 · Cited by 58
Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women
Voipio, S., Komi, J., Kangas, L., Halonen, K., DeGregorio, M. W., & Erkkola, R. (2002) · Maturitas · doi:10.1016/s0378-5122(02)00206-2 · Cited by 58
“However, HRT is associated with an increased risk of endometrial [3] and breast cancer [5].”
Background
Breast Augmentation: Compression—A Very Important Factor in Preventing Capsular Contracture
Camirand, A., Doucet, J., Harris, J., & Burkhardt, B. R. (1999) · Plastic & Reconstructive Surgery · doi:10.1097/00006534-199908000-00039 · Cited by 58
Mammographic Screening and Risk Factors for Breast Cancer
Cook, N. R., ROSNER, B. A., Hankinson, S. E., & Colditz, G. A. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp304 · Cited by 58
Reproductive and hormonal risk factors of breast cancer: a historical perspective
Horn, J., & VATTEN, L. J. (2017) · International Journal of Women s Health · doi:10.2147/ijwh.s129017 · Cited by 58
“may increase the risk of breast cancer, but results have not been consistent.(52,53) The Women’s Health Initiative was launched in 1992, and this randomized controlled trial was expected to solve the most important controversies related to the use of hormones during menopause.”
Comparative Effects of Estrogen and Angiotensin-Converting Enzyme Inhibition on Plasminogen Activator Inhibitor-1 in Healthy Postmenopausal Women
Brown, N. J., Abbas, A., Byrne, D. W., Schoenhard, J. A., & Vaughan, D. E. (2002) · Circulation · doi:10.1161/hc0302.102570 · Cited by 58
Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer and postmenopausal women
Moyad, M. A. (2002) · Urology · doi:10.1016/s0090-4295(02)01641-2 · Cited by 58
Ethnic differences in hormone replacement prescribing patterns
Brown, A. F., Pérez-Stable, E. J., Whitaker, E. E., Posner, S. F., Alexander, M., Gathe, J., & Washington, A. E. (1999) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.1999.10118.x · Cited by 58
Improving compliance with hormonal replacement therapy in primary osteoporosis prevention
Vestergaard, P., Hermann, A. P., Gram, J., Jensen, L. B., Kolthoff, N., Abrahamsen, B., Brot, C., & Eiken, P. (1997) · Maturitas · doi:10.1016/s0378-5122(97)00076-5 · Cited by 58
“The risk of breast cancer could also be considered to outweigh the reduced risk of cardiovascular death in some settings [13–15].”
Background
Alkylation of 2‘-Deoxynucleosides and DNA by the Premarin Metabolite 4-Hydroxyequilenin Semiquinone Radical
Shen, L., Qiu, S., Chen, Y., Zhang, F., van Breemen, R. B., Nikolic, D. S., & Bolton, J. L. (1998) · Chemical Research in Toxicology · doi:10.1021/tx970181r · Cited by 58
Postmenopausal Hormone Therapy as a Risk Factor for Gastroesophageal Reflux Symptoms Among Female Twins
Nordenstedt, H., Zheng, Z., Cameron, A. J., Ye, W., Pedersen, N. L., & Lagergren, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.009 · Cited by 57
The Adverse Effects of Hormone Replacement Therapy
Tavani, A., & Vecchia, C. L. (1999) · Drugs & Aging · doi:10.2165/00002512-199914050-00003 · Cited by 57
Psychosocial factors in the etiology of breast cancer: review of a popular link
Bleiker, E. M. A., & van der Ploeg, H. M. (1999) · Patient Education and Counseling · doi:10.1016/s0738-3991(99)00027-0 · Cited by 57
“Introduction use of menopausal estrogen replacement therapy [11,12].”
Background
From Adjuvant Therapy to Breast Cancer Prevention: BCPT and STAR
Dunn, B. K., & Ford, L. G. (2001) · The Breast Journal · doi:10.1046/j.1524-4741.2001.007003144.x · Cited by 57
Mammographic density changes in perimenopausal and postmenopausal women: is effect of hormone replacement therapy predictable?
Sterns, E. E., & Zee, B. C.-Y. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006326432340 · Cited by 57
Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat
Martel, C., Picard, S., Richard, V., Bélanger, A., Labrie, C., & Labrie, F. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00087-x · Cited by 57
“However, some undesirable effects are associated with chronic estrogen and progestin administration, including a perceived increased risk for uterine and/or breast cancer [6–9].”
Background
Dietary fat, fat subtypes, and breast cancer risk: lack of an association among postmenopausal women with no history of benign breast disease.
Byrne, C., Rockett, H. R. H., & Holmes, M. D. (2002) · PubMed · Cited by 57
Adherence to postmenopausal hormone therapy during the year after the initial prescription: A population-based study
Hill, D. A., Weiss, N. S., & LaCroix, A. Z. (2000) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(00)70210-9 · Cited by 57
Phyto-oestrogens through the life cycle
Cassidy, A., & Faughnan, M. S. (2000) · Proceedings of The Nutrition Society · doi:10.1017/s0029665100000719 · Cited by 59
“Hormone (oestrogen)-replacement therapy (HRT) is effective in symptom relief and has beneficial effects on the bone and vasculature, but is associated with a number of side effects including a slightly elevated risk of thrombosis, breast cancer and endometrial cancer (Colditz et al. 1995; Col et al. 1997).”
Background
Postmenopausal hormone therapy and breast cancer
Speroff, L. (1996) · Obstetrics and Gynecology · doi:10.1016/0029-7844(95)00428-9 · Cited by 57
Individualizing Therapy to Prevent Long-term Consequences of Estrogen Deficiency in Postmenopausal Women
Col, N. F., Pauker, S. G., Goldberg, R. J., Eckman, M. H., Orr, R. K., Ross, E. M., & Wong, J. B. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.13.1458 · Cited by 56
Association between breast cancer and bone mineral density: the Dubbo Osteoporosis Epidemiology Study
Nguyen, T. V., & Eisman, J. A. (2000) · Maturitas · doi:10.1016/s0378-5122(00)00133-x · Cited by 56
Efficacy of Levormeloxifene in the Prevention of Postmenopausal Bone Loss and on the Lipid Profile Compared to Low Dose Hormone Replacement Therapy1
Alexandersen, P., Riis, B. J., Stakkestad, J. A., Delmas, P. D., & Christiansen, C. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7214 · Cited by 56
Postmenopausal Estrogen-Containing Hormone Therapy and the Risk of Breast Cancer
Jick, S. S., Hagberg, K. W., Kaye, J. A., & Jick, H. (2009) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e31818fdde4 · Cited by 55
Update on cancer control in women
Boyle, P., Maisonneuve, P., & Autier, P. (2000) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(00)00298-8 · Cited by 55
A case-control study of hormone replacement therapy after primary surgical breast cancer treatment
Uršič-Vrščaj, M., & Bebar, S. (1999) · European Journal of Surgical Oncology · doi:10.1053/ejso.1998.0617 · Cited by 55
Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity
Dodge, J. A., Lugar, C. W., Cho, S., Short, L. L., Sato, M., Yang, N., Spangle, L. A., Martin, M. J., Phillips, D. L., Glasebrook, A. L., et al. (1997) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(97)00008-3 · Cited by 55
Antidepressant use and the risk of breast cancer
Wang, P. S., Walker, A. M., Tsuang, M. T., Orav, E. J., Levin, R., & Avorn, J. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00354-1 · Cited by 55
Breast Cancer
Colditz, G. A., Baer, H. J., & M., T. R. (2006) · doi:10.1093/acprof:oso/9780195149616.003.0051 · Cited by 54
Critical Appraisal of the Literature
Miser, W. F. (1999) · Journal of the American Board of Family Medicine · doi:10.3122/jabfm.12.4.315 · Cited by 96
“6o The four major clinical categories found in articles of primary (original) research are (1) therapy, (2) diagnosis and screening, (3) causation, and (4) prognosis (Table 2).”
BackgroundMethodInfluential
Oral bisphosphonates in the treatment of osteoporosis: a review
Francis, R. M. (1995) · Current Therapeutic Research · doi:10.1016/0011-393x(95)85087-2 · Cited by 54
p -Quinone methides are the major decomposition products of catechol estrogen o -quinones
Bolton, J. L., & Shen, L. (1996) · Carcinogenesis · doi:10.1093/carcin/17.5.925 · Cited by 54
Predominant androgenic component in the stimulatory effect of dehydroepiandrosterone on bone mineral density in the rat
Martel, C., Sourla, A., Pelletier, G., Labrie, C., Fournier, M., Picard, S., Li, S., Stojanovic, M. M., & Labrie, F. (1998) · Journal of Endocrinology · doi:10.1677/joe.0.1570433 · Cited by 54
Bias in Breast Cancer Analyses Due to Error in Age at Menopause
Rockhill, B., Colditz, G. A., & ROSNER, B. A. (2000) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010220 · Cited by 54
“They note that previous analyses of breast cancer risk conducted in the Nurses' Health Study (2, 3)”
Result
Approaches for Conducting Large Cohort Studies
Willett, W. C., & Colditz, G. A. (1998) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a017975 · Cited by 52
Guidelines for the Management of Patients with Acute Myocardial Infarction
Becker, R. C., & Spencer, F. (1998) · Journal of Thrombosis and Thrombolysis · doi:10.1023/a:1008809723703 · Cited by 53
Mammographic Changes in Women Receiving Tibolone Therapy
Erel, C. T., Elter, K., Akman, C., Ersavaşti, G., Altuğ, A., Seyisoğlu, H., & Ertüngealp, E. (1998) · Fertility and Sterility · doi:10.1016/s0015-0282(98)00051-x · Cited by 53
Healthy aging. A women's issue.
LaCroix, A. Z., Newton, K. M., Leveille, S. G., & Wallace, J. G. (1997) · PubMed Central · Cited by 52
Progestins and breast cancer
Eden, J. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2003.201 · Cited by 52
Menopause Research and The Dominance of the Biomedical Model 1984-1994
Rostosky, S. S., & Travis, C. B. (1996) · Psychology of Women Quarterly · doi:10.1111/j.1471-6402.1996.tb00471.x · Cited by 52
Interplay Between Insulin Resistance and Estrogen Deficiency as co- Activators in Carcinogenesis
Suba, Z. (2011) · Pathology & Oncology Research · doi:10.1007/s12253-011-9466-8 · Cited by 55
Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson's disease in men and women
Palacios, N., Weisskopf, M. G., Simon, K., Gao, X., Schwarzschild, M. A., & Ascherio, A. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.02.012 · Cited by 51
“The validity of reported PMH use in this study is supported by prior reports of strong significant associations between this variable and ovarian and breast cancer in the NHS cohort [17,18].”
Result
Hormone replacement therapy and breast cancer risk in a nationally representative cohort
Lando, J. F., Heck, K. E., & Brett, K. M. (1999) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(99)00078-1 · Cited by 51
Trends of Postmenopausal Estrogen Plus Progestin Prevalence in the United States Between 1970 and 2010
Jewett, P. I., Gangnon, R. E., Trentham‐Dietz, A., & Sprague, B. L. (2014) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000000469 · Cited by 51
Synthesis of bone-targeted oestrogenic compounds for the inhibition of bone resorption
Page, P. C. B., Moore, J. P. G., Mansfield, I., McKenzie, M. J., Bowler, W. B., & Gallagher, J. A. (2001) · Tetrahedron · doi:10.1016/s0040-4020(00)01164-9 · Cited by 51
Effects of two estradiol regimens on anxiety and depressive behaviors and trophic effects in peripheral tissues in a rodent model
Walf, A. A., & Frye, C. A. (2009) · Gender Medicine · doi:10.1016/j.genm.2009.04.004 · Cited by 50
Disparities in Hormone Replacement Therapy Use by Socioeconomic Status in a Primary Care Population
Finley, C. A., Gregg, E. W., Solomon, L. J., & Gay, E. (2001) · Journal of Community Health · doi:10.1023/a:1026537114638 · Cited by 50
THE GENETIC BASIS OF BREAST CANCER AND ITS CLINICAL IMPLICATIONS
Bennett, I., Gattas, M. R., & Teh, B. T. (1999) · Australian and New Zealand Journal of Surgery · doi:10.1046/j.1440-1622.1999.01515.x · Cited by 47
Raloxifene enhances nitric oxide release in rat aorta via increasing endothelial nitric oxide mRNA expression
Rahimian, R., Dubé, G. P., Toma, W., Santos, N. D., McManus, B. M., & van Breemen, C. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01546-1 · Cited by 50
Current and potential future drug treatments for osteoporosis.
Patel, S. K. (1996) · Annals of the Rheumatic Diseases · doi:10.1136/ard.55.10.700 · Cited by 50
Instructional Course Lectures, The American Academy of Orthopaedic Surgeons - Osteoporosis
Lane, J. M., Riley, E. H., & Wirganowicz, P. Z. (1996) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-199604000-00019 · Cited by 50
Task force 4. Efficacy of risk factor management
Forrester, J. S., Merz, C. N. B., Bush, T. L., Cohn, J. N., Hunninghake, D. B., Parthasarathy, S., & Superko, H. R. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(96)87732-1 · Cited by 50
INTERACTIONS BETWEEN HORMONES AND CHEMICALS IN BREAST CANCER
Safe, S. H. (1998) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.121 · Cited by 51
Hormone replacement therapy: determinants of women's decisions
Marmoreo, J., Brown, J. B., Batty, H. R., Cummings, S., & Powell, M. (1998) · Patient Education and Counseling · doi:10.1016/s0738-3991(98)00028-7 · Cited by 50
The effect of raloxifene on bone marrow adipose tissue and bone turnover in postmenopausal women with osteoporosis
Beekman, K. M., Veldhuis‐Vlug, A. G., den Heijer, M., Maas, M. M., Oleksik, A. M., Tanck, M. W. T., Ott, S. M., Hof, R. V., Lips, P. T. A. M., Bisschop, P. H. L. T., et al. (2017) · Bone · doi:10.1016/j.bone.2017.10.011 · Cited by 49
Anti-oestrogenic prevention of breast cancer — the make or break point
Powles, T. J. (2002) · Nature reviews. Cancer · doi:10.1038/nrc908 · Cited by 49
Cyclic changes in the mammary gland of cynomolgus macaques
Stute, P., Wood, C. E., Kaplan, J. R., & Cline, J. M. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.04.035 · Cited by 49
Phytoestrogens as Therapeutic Alternatives to Traditional Hormone Replacement in Postmenopausal Women
Umland, E. M., Cauffield, J. S., Kirk, J. K., & Thomason, T. E. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.11.981.35259 · Cited by 49
Menopausal Hormone Therapy
Bhavnani, B. R., & Strickler, R. C. (2005) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)30186-4 · Cited by 49
Hormones and Cognition: Current Concepts and Issues in Neuropsychology
Erlanger, D. M., Kutner, K. C., & Jacobs, A. R. (1999) · Neuropsychology Review · doi:10.1023/a:1021634622577 · Cited by 49
“Despite these potential benefits, a controversy exists regarding the utility of ERT for women with a family history of breast cancer (see Colditz et al., 1995; Grady and Ernster, 1991).”
Background
Endocrine and paracrine hormones in the promotion, progression and recurrence of breast cancer
Reid, S. E., Murthy, M. S., Kaufman, M. W., & Scanlon, E. F. (1996) · British journal of surgery · doi:10.1002/bjs.1800830805 · Cited by 49
Effect of physician gender on the prescription of estrogen replacement therapy
Seto, T. B., Taira, D. A., Davis, R. B., Safran, C., & Phillips, R. S. (1996) · Journal of General Internal Medicine · doi:10.1007/bf02642475 · Cited by 49
Hormone replacement therapy and the risk of breast cancer
Cuzick, J. M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.07.041 · Cited by 48

Authors: Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E.
Affiliations: Brigham and Women's Hospital (US)
ORCID: Colditz, Graham A.
Hankinson, Susan E.
Willett, Walter C.
Manson, JoAnn E.
Stampfer, Meir J.
Hennekens, Charles
Rosner, Bernard
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1995-06-15
Volume: 332
Issue: 24
Pages: 1589-1593
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199506153322401
OpenAlex: W2607238143
Cited by: 1,487
References: 32
Citations by year: 2026: 5 · 2025: 4 · 2024: 6 · 2023: 8 · 2022: 8 · 2021: 13 · 2020: 13 · 2019: 11 · 2018: 17 · 2017: 16 · 2016: 16 · 2015: 18 · 2014: 21 · 2013: 18 · 2012: 26
FWCI: 111.38
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (CA 40956)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Oncology › Cancer Risks and Factors
Keywords: breast cancer risk, hormone replacement therapy, estrogen therapy, progestins, estrogen plus progestin, duration of hormone use, age-related risk, breast cancer mortality, Nurses' Health Study
MeSH terms: Aged, Breast Neoplasms, Estrogens, Female, Follow-Up Studies, Humans, Middle Aged, Progestins, Prospective Studies, Risk, Risk Factors, Cohort Studies, Estrogen Replacement Therapy, Confidence Intervals, Case-Control Studies, Postmenopause

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks